Medicare's 2026 Double-Take: Drug Savings vs. Soaring Premiums
While new drug price negotiations offer a glimmer of hope, seniors brace for higher Part B costs, creating a complex financial tightrope.
The direct answer
The Centers for Medicare & Medicaid Services (CMS) has finalized payment policies for Medicare Advantage and Part D plans for contract year 2027, signaling a mixed bag for beneficiaries. On one hand, the Inflation Reduction Act's provisions are taking hold, introducing a $2,000 out-of-pocket cap on prescription drugs for Part D beneficiaries and enabling Medicare to negotiate prices for certain high-cost medications
$UNH $CLOV $HUM $ALHC Today CMS dropped its final rule for how Medicare Advantage and Part D drug plans will work starting in contract year 2027, and there are some meaningful takeaways for anyone holding shares in companies like UnitedHealth, Humana, or Clover Health. The…
— Albert Alan, MD link
. This aims to provide significant relief for those managing chronic conditions with expensive treatments. However, this potential savings is juxtaposed against anticipated increases in Medicare Part B premiums and deductibles. While specific figures for 2026 are still solidifying, preliminary indications and historical trends suggest a rise, potentially offsetting drug cost reductions for some seniors
Centers for Medicare & Medicaid Services (CMS) Reports Finalizing 2027 Medicare Advantage and Part D Payment Policies Saying it Strengthens Accountability and Long-Term Sustainability https://t.co/3nqV9lpVUS
— SIERRA SUN TIMES link
. The CMS did finalize a 2.48% average increase in 2027 Medicare Advantage payments, which is above expectations and could signal stability for those plans, but it doesn't directly address the Part B premium hike for traditional Medicare
$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh
— Wall St Engine link
. This creates a complex financial planning scenario where the benefits of drug negotiation might not fully materialize for every senior.
The Drug Price Negotiation Gambit
The headline grabber for 2026 is undoubtedly the new ability for Medicare to negotiate prices for a select group of high-cost prescription drugs, a power amplified by the Inflation Reduction Act. This move is designed to curb the runaway costs of certain medications and is coupled with a new annual out-of-pocket maximum of $2,000 for Part D prescription drug costs, starting in 2027
$UNH $CLOV $HUM $ALHC Today CMS dropped its final rule for how Medicare Advantage and Part D drug plans will work starting in contract year 2027, and there are some meaningful takeaways for anyone holding shares in companies like UnitedHealth, Humana, or Clover Health. The…
— Albert Alan, MD link
. This cap is a crucial safeguard, particularly for individuals managing chronic conditions that require expensive, ongoing treatments. The hope is that negotiated prices, combined with the cap, will provide substantial financial relief. However, the selection of drugs for negotiation is initially limited, and the full impact will take years to materialize as more drugs become eligible. The industry's initial reaction, as seen in stock movements for companies like UnitedHealth and Humana, suggests they are factoring these changes into their long-term strategies [c1, c2].
The Hidden Costs: Part B Premiums and Deductibles
While the focus is on prescription drug savings, seniors must also contend with the persistent creep of Part B costs. Medicare Part B covers physician services, outpatient care, and durable medical equipment. Its premiums and deductibles are subject to annual adjustments, and for 2026, an increase is widely anticipated. Although the final figures are pending, historical patterns suggest a notable rise that could significantly impact a senior's fixed income
Centers for Medicare & Medicaid Services (CMS) Reports Finalizing 2027 Medicare Advantage and Part D Payment Policies Saying it Strengthens Accountability and Long-Term Sustainability https://t.co/3nqV9lpVUS
— SIERRA SUN TIMES link
. This is not a new phenomenon; premiums have steadily climbed over the years, often outpacing inflation adjustments for Social Security benefits. The contrast between the projected drug savings and the certainty of rising Part B costs presents a challenging financial landscape, forcing beneficiaries to weigh immediate expenses against future potential savings.
Medicare Advantage vs. Traditional Medicare: A Diverging Path?
The CMS's final rule for 2027 indicates a 2.48% average increase in Medicare Advantage payments
$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh
— Wall St Engine link
. This figure, higher than some industry analysts expected, suggests a degree of stability and potential profitability for Medicare Advantage plans, which often bundle Part D drug coverage and may have their own out-of-pocket limits. For beneficiaries enrolled in these plans, the impact of the new Part D cap and negotiated drug prices will be directly integrated. However, this does not directly translate to relief for the roughly 25 million Americans enrolled in traditional Medicare. These individuals rely on original Medicare and likely a separate Part D plan, making them more directly exposed to the fluctuations in Part B premiums and deductibles, and the specific terms of their chosen Part D plan for drug costs
Centers for Medicare & Medicaid Services (CMS) Reports Finalizing 2027 Medicare Advantage and Part D Payment Policies Saying it Strengthens Accountability and Long-Term Sustainability https://t.co/3nqV9lpVUS
— SIERRA SUN TIMES link
. The divergence highlights the complexity of navigating Medicare's dual systems.
Common mistakes
- Focusing solely on the drug price negotiation benefits.
This overlooks the equally significant, and potentially offsetting, increases in Part B premiums and deductibles that many seniors will face, creating a false sense of overall savings. - Presenting Medicare Advantage and Traditional Medicare impacts as uniform.
The payment adjustments for Medicare Advantage plans [c2] do not directly translate to the cost experience for beneficiaries in traditional Medicare, who are more exposed to Part B premium and deductible hikes. - Using vague language about future costs.
Instead of saying 'costs may rise,' specific examples of how Part B premiums and deductibles have historically increased, and the potential dollar impact, are more informative for financial planning.
$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh
— Wall St Engine link
does little to comfort those in traditional Medicare facing rising monthly costs. It’s a classic bait-and-switch: touting a future benefit while imposing an immediate, tangible cost. This strategy benefits insurers and pharmaceutical companies by creating a complex system where true savings are hard-won and often elusive for the average beneficiary.
Frequently asked
Will my Medicare Part B premium go up in 2026?
While final figures for 2026 Medicare Part B premiums and deductibles are typically announced in the fall, historical trends and preliminary indications suggest an increase is likely. This rise could offset some of the savings gained from the new Part D out-of-pocket cap and drug price negotiations.
How much will I save on prescription drugs with the new Medicare changes?
Starting in 2027, your out-of-pocket prescription drug costs in Part D will be capped at $2,000 annually. Additionally, Medicare will begin negotiating prices for a select number of high-cost drugs, which could further reduce costs for those specific medications over time [c1].
Does the 2.48% increase in Medicare Advantage payments affect my traditional Medicare costs?
No, the 2.48% average increase in Medicare Advantage payments for 2027 [c2] primarily impacts the financial structure of Medicare Advantage plans. It does not directly alter the premiums or deductibles for beneficiaries enrolled in traditional Medicare, who will still face adjustments to their Part B costs.
Sources
More from Healthcare Policy → · Back to Perch · Browse all stories